Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

Instacart outlines $9.45B–$9.6B Q4 GTV target while expanding enterprise and AI initiatives

View original at seekingalpha.com
Instacart outlines $9.45B–$9.6B Q4 GTV target while expanding enterprise and AI initiatives Earnings Call Insights: Maplebear Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stock-based compensation in Q3 was $82 million, down $24 million quarter-over-quarter, and expected to normalize to Q2 2025 levels in Q4

    80% confidence
  • Exclusivity with retailers is less important than the depth of enterprise relationships

    80% confidence
  • Q3 orders reached 83.4 million, up 14% year-over-year, driving GTV of $9.17 billion, up 10% year-over-year

    80% confidence
  • International expansion is the right moment, taking existing technology and extending it to retailers beyond North America

    80% confidence
  • Price parity retailers are growing 10 percentage points faster versus marked-up retailers

    80% confidence
  • Instacart+ is a critical part of overall strategy with continued growth and engagement

    80% confidence
  • Instacart continues to grow in markets where Amazon competes and is not seeing a shift in basket composition

    80% confidence
  • NYC represents a small percentage of GTV and Instacart expects to navigate regulatory changes successfully

    80% confidence
  • Q4 adjusted EBITDA guidance is $285 million to $295 million

    80% confidence
  • 75% of the market is still in large baskets, $75 and above

    80% confidence
  • GAAP net income was $144 million, up 22% year-over-year, and adjusted EBITDA also grew 22% year-over-year to $278 million

    80% confidence
  • Advertising and other revenue will return to double-digit growth in 2026

    80% confidence
  • Instacart's storefront or white label e-commerce technologies now power more than 350 retailer e-commerce storefronts

    80% confidence
  • Instacart is the leading online grocery marketplace with a best-in-class suite of enterprise technologies for retailers and a growing advertising ecosystem

    80% confidence
  • Three strategic investment areas are affordability, accelerating enterprise, and ads and data

    80% confidence
  • Instacart drove over $1 billion of ads and other revenue over the past 12 months

    80% confidence
  • Over 80% of Instacart's business is nonexclusive today, and the majority of those have an enterprise relationship

    80% confidence
  • Q4 GTV is anticipated to range between $9.45 billion to $9.6 billion, representing 9% to 11% year-over-year growth

    80% confidence
  • Large basket growth (75% of the market) remains consistent

    80% confidence
  • Instacart is confident in reaching 4%-5% long-term ad take rates through platform and ecosystem expansion

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Instacart outlines $9.45B–$9.6B Q4 GTV target while expanding enterprise and AI initiatives — Source | Via News | ViaNews EU